Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Plus Therapeutics (PSTV)
:PSTV
Holding PSTV?
Track your performance easily
PSTV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.93 - $2.67
Previous CloseN/A
Volume69.06K
Average Volume (3M)51.58K
Market Cap
$7.02M
Enterprise Value$10.08M
Total Cash (Recent Filing)$12.56M
Total Debt (Recent Filing)$11.01M
Price to Earnings (P/E)―
Beta2.47
Next Earnings
Feb 20, 2025EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.24
Shares Outstanding5,896,333
10 Day Avg. Volume31,894
30 Day Avg. Volume51,577
Standard Deviation0.21
R-Squared0.03
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.22
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.44
Enterprise Value/Revenue2.28
Enterprise Value/Gross Profit2.05
Enterprise Value/Ebitda-0.90
Forecast
1Y Price Target
$10.25Price Target Upside776.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Plus Therapeutics News
PremiumCompany Announcements
Plus Therapeutics Advances Radiotherapeutics in Q3 2024Bulls Say, Bears Say
Bulls Say
Clinical TrialsRhenium obisbemeda was granted orphan drug designation by the FDA for the treatment of breast cancer with leptomeningeal metastases, highlighting its potential and importance in addressing unmet medical needs.
Financial PerformanceThe company reported a net loss of $0.37 per share, which was better than the consensus estimated net loss of $0.56 per share, reflecting improved financial performance.
Partnerships And CollaborationsEntered into a Research and Collaborative Agreement with Brainlab to implement software for CED of Re-186-Obisbemeda, enhancing treatment delivery and precision.
Bears Say
Capital RaisingFuture capital raises are now estimated to occur at significantly lower share prices than previously anticipated.
Financial PerformanceManagement did not provide 2024 guidance, but current quarterly cash burn is estimated at ~$3 million.
Stock ValuationThe price target has been decreased to $10 from $32 due to a dilutive effect from lower prices of future capital raises.
---
Ownership Overview
12.45% Insiders
1.32% Mutual Funds
9.73% Other Institutional Investors
75.95% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PSTV FAQ
What was Plus Therapeutics’s price range in the past 12 months?
Plus Therapeutics lowest stock price was $0.93 and its highest was $2.67 in the past 12 months.
What is Plus Therapeutics’s market cap?
Plus Therapeutics’s market cap is $7.02M.
When is Plus Therapeutics’s upcoming earnings report date?
Plus Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is in 33 days.
How were Plus Therapeutics’s earnings last quarter?
Plus Therapeutics released its earnings results on Nov 14, 2024. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.562 by $0.192.
Is Plus Therapeutics overvalued?
According to Wall Street analysts Plus Therapeutics’s price is currently Undervalued.
Does Plus Therapeutics pay dividends?
Plus Therapeutics does not currently pay dividends.
What is Plus Therapeutics’s EPS estimate?
Plus Therapeutics’s EPS estimate is -0.4.
How many shares outstanding does Plus Therapeutics have?
Plus Therapeutics has 5,896,333 shares outstanding.
What happened to Plus Therapeutics’s price movement after its last earnings report?
Plus Therapeutics reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.562. Following the earnings report the stock price went down -7.143%.
Which hedge fund is a major shareholder of Plus Therapeutics?
Currently, no hedge funds are holding shares in PSTV
---
Company Description
Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and manufacturing scale up of complex and innovative treatments for patients battling cancer and other life-threatening diseases. The proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. The lead drug product candidate in pipeline, DocePLUS™, is being developed in the U.S. by a dedicated and energetic team of biologists, chemists, engineers, and other professionals. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.
---
PSTV Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with significant clinical progress and grant support as highlights, while financial challenges such as decreased cash reserves and increased operating losses as lowlights.Read More>---
PSTV Stock 12 Month Forecast
Average Price Target
$10.25
▲(776.07% Upside)
Technical Analysis
Best Analysts Covering PSTV
1 Year
1 Year Success Rate
1/16 ratings generated profit
1 Year Average Return
-53.83%
reiterated a buy rating 2 months ago
Copying Sean Lee CFA's trades and holding each position for 1 Year would result in 6.25% of your transactions generating a profit, with an average return of -53.83% per trade.
---